Notably, these results successfully translated into a phase 2 clinical study, as daily treatment with a single tablet of baricitinib for over 48 weeks successfully preserved C-peptide in recent-onset T1D patients and reduced exogenous basal and prandial insulin intake with minimal adverse events (Waibel et al, 2023). This evidence concerns the gene INS and type 1 diabetes mellitus.